Anti-Tuberculosis Drug Induced Hepatotoxicity and Associated Factors among Tuberculosis Patients at Selected Hospitals, Ethiopia.
anti-tuberculosis drugs
hepatotoxicity
tuberculosis
Journal
Hepatic medicine : evidence and research
ISSN: 1179-1535
Titre abrégé: Hepat Med
Pays: New Zealand
ID NLM: 101544801
Informations de publication
Date de publication:
2021
2021
Historique:
received:
23
11
2020
accepted:
15
12
2020
entrez:
4
2
2021
pubmed:
5
2
2021
medline:
5
2
2021
Statut:
epublish
Résumé
Tuberculosis caused by susceptible mycobacterium tuberculosis strains is effectively treated by the first-line anti-tuberculosis drugs. However, most antibacterial drugs are known to induce hepatotoxicity which may limit their adherence and hence lead to the development of mycobacterial drug resistance. The aim of this study was to assess the incidence of anti-tuberculosis drug induced hepatotoxicity and associated factors among tuberculosis patients of Debre Markos, Mota, and Bichena Hospitals. The prospective cross sectional-study was conducted in three hospitals of East Gojjam zone by taking blood samples of new tuberculosis patients every 2 weeks for 2 months to measure the elevation of liver proteins indicating liver toxicity from the onset of starting therapy. A semi-structured questionnaire was also used to collect the socio-demographic data and factors of anti-tubeculosis drug induced liver toxicity. To identify factors associated with drug induced hepatotoxicity, binary logistic regression followed by multivariate analysis was applied at a statistically significant level of The incidence of hepatotoxicity among tuberculosis patients is 7.9%. Diagnosis of extrapulmonary tuberculosis, having comorbid disease, and old age are significantly associated ( The incidence of hepatotoxicity is relatively high among tuberculosis patients taking first-line anti-tuberculosis drugs. Therefore, the liver function of patients with old age, comorbid diseases, and extrapulmonary tuberculosis should be regularly monitored to reduce the severity of drug-induced hepatotoxicity.
Sections du résumé
BACKGROUND
BACKGROUND
Tuberculosis caused by susceptible mycobacterium tuberculosis strains is effectively treated by the first-line anti-tuberculosis drugs. However, most antibacterial drugs are known to induce hepatotoxicity which may limit their adherence and hence lead to the development of mycobacterial drug resistance.
OBJECTIVE
OBJECTIVE
The aim of this study was to assess the incidence of anti-tuberculosis drug induced hepatotoxicity and associated factors among tuberculosis patients of Debre Markos, Mota, and Bichena Hospitals.
METHODS
METHODS
The prospective cross sectional-study was conducted in three hospitals of East Gojjam zone by taking blood samples of new tuberculosis patients every 2 weeks for 2 months to measure the elevation of liver proteins indicating liver toxicity from the onset of starting therapy. A semi-structured questionnaire was also used to collect the socio-demographic data and factors of anti-tubeculosis drug induced liver toxicity. To identify factors associated with drug induced hepatotoxicity, binary logistic regression followed by multivariate analysis was applied at a statistically significant level of
RESULTS
RESULTS
The incidence of hepatotoxicity among tuberculosis patients is 7.9%. Diagnosis of extrapulmonary tuberculosis, having comorbid disease, and old age are significantly associated (
CONCLUSION
CONCLUSIONS
The incidence of hepatotoxicity is relatively high among tuberculosis patients taking first-line anti-tuberculosis drugs. Therefore, the liver function of patients with old age, comorbid diseases, and extrapulmonary tuberculosis should be regularly monitored to reduce the severity of drug-induced hepatotoxicity.
Identifiants
pubmed: 33536799
doi: 10.2147/HMER.S290542
pii: 290542
pmc: PMC7850419
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1-8Informations de copyright
© 2021 Molla et al.
Déclaration de conflit d'intérêts
The authors declare that they have no competing interests.
Références
Am J Respir Crit Care Med. 2006 Oct 15;174(8):935-52
pubmed: 17021358
Biomed Res Int. 2019 Aug 18;2019:8764093
pubmed: 31531370
Bull World Health Organ. 2001;79(4):373-4
pubmed: 11357217
Antimicrob Agents Chemother. 2018 Sep 24;62(10):
pubmed: 30249717
Int J Mycobacteriol. 2016 Mar;5(1):14-20
pubmed: 26927985
Singapore Med J. 2008 Sep;49(9):688-93
pubmed: 18830542
Am J Respir Crit Care Med. 2003 Jun 1;167(11):1472-7
pubmed: 12569078
Pan Afr Med J. 2016 Nov 16;25:167
pubmed: 28292129
Tubercle. 1986 Jun;67(2):99-108
pubmed: 3775870
Thorax. 1998 Jul;53(7):536-48
pubmed: 9797751
Hepatol Int. 2008 Sep;2(3):353-60
pubmed: 19669265
Am J Respir Crit Care Med. 1998 Jun;157(6 Pt 1):1871-6
pubmed: 9620920
PLoS One. 2013 May 16;8(5):e64622
pubmed: 23696901
Br J Nutr. 2011 Feb;105(3):400-8
pubmed: 20875187
J Clin Exp Hepatol. 2013 Mar;3(1):37-49
pubmed: 25755470
Int J Tuberc Lung Dis. 2004 Dec;8(12):1499-505
pubmed: 15636498
BMC Infect Dis. 2018 Aug 29;18(1):431
pubmed: 30157783
J Ayub Med Coll Abbottabad. 2014 Jul-Sep;26(3):384-8
pubmed: 25671954
Am J Respir Crit Care Med. 2002 Oct 1;166(7):916-9
pubmed: 12359646
Trop Gastroenterol. 2011 Jul-Sep;32(3):167-74
pubmed: 22332331
J Gastroenterol Hepatol. 2008 Feb;23(2):192-202
pubmed: 17995946
BMC Infect Dis. 2019 Jun 28;19(1):564
pubmed: 31253115
PLoS One. 2008 Mar 19;3(3):e1809
pubmed: 18350147